NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis → Putin and other countries have a plan (From Whats On Finance) (Ad) Free CTMX Stock Alerts $1.68 +0.02 (+0.90%) (As of 03:33 PM ET) Add Compare Share Share Today's Range$1.64▼$1.7350-Day Range$1.41▼$2.7452-Week Range$1.04▼$2.86Volume179,074 shsAverage Volume838,890 shsMarket Capitalization$114.13 millionP/E RatioN/ADividend YieldN/APrice Target$3.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CytomX Therapeutics alerts: Email Address CytomX Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside84.2% Upside$3.10 Price TargetShort InterestHealthy4.90% of Shares Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews Sentiment0.76Based on 9 Articles This WeekInsider TradingSelling Shares$73,200 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.21) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.31 out of 5 starsMedical Sector120th out of 910 stocksPharmaceutical Preparations Industry41st out of 426 stocks 3.2 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.90% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytomX Therapeutics has recently decreased by 5.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CytomX Therapeutics is -0.74. Previous Next 2.6 News and Social Media Coverage News SentimentCytomX Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,200.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.21) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -83.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -83.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About CytomX Therapeutics Stock (NASDAQ:CTMX)CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More CTMX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTMX Stock News HeadlinesApril 23, 2024 | msn.comJP Morgan Upgrades CytomX Therapeutics (CTMX)April 23, 2024 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Upgraded to "Neutral" at JPMorgan Chase & Co.April 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 22, 2024 | msn.comCytomX upgraded to Neutral at J.P MorganApril 18, 2024 | americanbankingnews.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 5.9% in MarchApril 17, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (CTMX)April 8, 2024 | globenewswire.comCytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsApril 3, 2024 | globenewswire.comCytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasApril 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 23, 2024 | investing.comCytomX Therapeutics executive sells over $26k in company stockMarch 23, 2024 | investing.comCytomX Therapeutics executive sells shares worth over $6,000March 21, 2024 | globenewswire.comCytomX Therapeutics Appoints Dr. Zhen Su to Board of DirectorsMarch 18, 2024 | globenewswire.comCytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasMarch 13, 2024 | finance.yahoo.comCytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 12, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Legend Biotech (LEGN) and CytomX Therapeutics (CTMX)March 12, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Sell Rating on CytomX Therapeutics (CTMX)March 12, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | investorplace.comWhy Is CytomX Therapeutics (CTMX) Stock Down 18% Today?March 12, 2024 | benzinga.comWhy Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketMarch 11, 2024 | marketwatch.comStocks to Watch: Oracle, Mission Produce, CytomX TherapeuticsMarch 11, 2024 | marketwatch.comCytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing CandidateMarch 11, 2024 | benzinga.comRecap: CytomX Therapeutics Q4 EarningsMarch 11, 2024 | globenewswire.comCytomX Therapeutics Reports 2023 Financial Results and Provides Business UpdateMarch 8, 2024 | benzinga.comCytomX Therapeutics's Earnings OutlookMarch 4, 2024 | globenewswire.comCytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024February 28, 2024 | ca.finance.yahoo.comBMY Oct 2024 45.000 putFebruary 27, 2024 | ca.finance.yahoo.comBMY Apr 2024 52.000 putSee More Headlines Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTMX CUSIPN/A CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees120Year FoundedN/APrice Target and Rating Average Stock Price Target$3.10 High Stock Price Target$3.19 Low Stock Price Target$3.00 Potential Upside/Downside+85.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,000.00 Net Margins-0.56% Pretax Margin3.28% Return on EquityN/A Return on Assets-0.26% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio1.17 Sales & Book Value Annual Sales$101.21 million Price / Sales1.12 Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-2.35Miscellaneous Outstanding Shares67,730,000Free Float62,991,000Market Cap$113.11 million OptionableOptionable Beta1.01 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Sean A. McCarthy DPHIL (Age 57)Chairman & CEO Comp: $1.03MKey CompetitorsVistagen TherapeuticsNASDAQ:VTGNEliem TherapeuticsNASDAQ:ELYMKaryopharm TherapeuticsNASDAQ:KPTINuvectis PharmaNASDAQ:NVCTRepare TherapeuticsNASDAQ:RPTXView All CompetitorsInsiders & InstitutionsCongress Park Capital LLCSold 5,500 shares on 4/16/2024Ownership: 0.345%Sean A MccarthySold 20,223 sharesTotal: $42,266.07 ($2.09/share)Lloyd A RowlandSold 5,268 sharesTotal: $11,010.12 ($2.09/share)Jeffrey B LandauSold 6,562 sharesTotal: $13,714.58 ($2.09/share)Christopher OgdenSold 2,971 sharesTotal: $6,209.39 ($2.09/share)View All Insider TransactionsView All Institutional Transactions CTMX Stock Analysis - Frequently Asked Questions Should I buy or sell CytomX Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares. View CTMX analyst ratings or view top-rated stocks. What is CytomX Therapeutics' stock price target for 2024? 3 brokers have issued twelve-month price targets for CytomX Therapeutics' stock. Their CTMX share price targets range from $3.00 to $3.19. On average, they predict the company's stock price to reach $3.10 in the next year. This suggests a possible upside of 84.2% from the stock's current price. View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts. How have CTMX shares performed in 2024? CytomX Therapeutics' stock was trading at $1.55 on January 1st, 2024. Since then, CTMX shares have increased by 8.4% and is now trading at $1.68. View the best growth stocks for 2024 here. Are investors shorting CytomX Therapeutics? CytomX Therapeutics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 3,320,000 shares, a decrease of 5.9% from the March 15th total of 3,530,000 shares. Based on an average daily volume of 864,800 shares, the days-to-cover ratio is presently 3.8 days. View CytomX Therapeutics' Short Interest. When is CytomX Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our CTMX earnings forecast. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings data on Monday, March, 11th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.01. The biotechnology company had revenue of $26.61 million for the quarter, compared to analyst estimates of $23.36 million. What ETF holds CytomX Therapeutics' stock? Formidable ETF holds 282,099 shares of CTMX stock, representing 1.88% of its portfolio. What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO? 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX). Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Congress Park Capital LLC (0.35%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CTMX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
